CA3096188C - Identification of tumour-associated cell surface antigens for diagnosis and therapy - Google Patents

Identification of tumour-associated cell surface antigens for diagnosis and therapy Download PDF

Info

Publication number
CA3096188C
CA3096188C CA3096188A CA3096188A CA3096188C CA 3096188 C CA3096188 C CA 3096188C CA 3096188 A CA3096188 A CA 3096188A CA 3096188 A CA3096188 A CA 3096188A CA 3096188 C CA3096188 C CA 3096188C
Authority
CA
Canada
Prior art keywords
tumor
nucleic acid
associated antigen
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA3096188A
Other languages
English (en)
French (fr)
Other versions
CA3096188A1 (en
Inventor
Ozlem Tureci
Ugur Sahin
Gerd Helftenbein
Volker Schluter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of CA3096188A1 publication Critical patent/CA3096188A1/en
Application granted granted Critical
Publication of CA3096188C publication Critical patent/CA3096188C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
CA3096188A 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy Expired - Lifetime CA3096188C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10344799.7 2003-09-26
DE10344799A DE10344799A1 (de) 2003-09-26 2003-09-26 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CA2984653A CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2984653A Division CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Publications (2)

Publication Number Publication Date
CA3096188A1 CA3096188A1 (en) 2005-04-07
CA3096188C true CA3096188C (en) 2022-06-07

Family

ID=34306102

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3096188A Expired - Lifetime CA3096188C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2539837A Expired - Lifetime CA2539837C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2984653A Expired - Lifetime CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2814269A Expired - Lifetime CA2814269C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA2539837A Expired - Lifetime CA2539837C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2984653A Expired - Lifetime CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2814269A Expired - Lifetime CA2814269C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Country Status (8)

Country Link
US (6) US7875424B2 (OSRAM)
EP (22) EP2267012B1 (OSRAM)
JP (5) JP5144933B2 (OSRAM)
AU (1) AU2004275500B2 (OSRAM)
CA (4) CA3096188C (OSRAM)
DE (1) DE10344799A1 (OSRAM)
ES (1) ES2634705T3 (OSRAM)
WO (1) WO2005030250A2 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2004276646B2 (en) * 2003-09-29 2012-07-12 Chugai Seiyaku Kabushiki Kaisha Protein expressed in NK cell
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP2009502112A (ja) * 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 腎細胞癌を診断および処置するための方法
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8404810B2 (en) * 2006-02-17 2013-03-26 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
ES2582208T3 (es) 2008-10-27 2016-09-09 Sapporo Medical University Marcador molecular para células madre cancerosas
WO2011051271A2 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Prostate tumor markers and methods of use thereof
US20130017546A1 (en) 2009-10-26 2013-01-17 Externautics S.P.A. Breast Tumor Markers and Methods of Use Thereof
US20120322075A1 (en) 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
WO2011051280A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Ovary tumor markers and methods of use thereof
US20130022983A1 (en) 2009-10-26 2013-01-24 Externautics S.P.A. Colon and Rectal Tumor Markers and Methods of Use Thereof
FR2973380B1 (fr) * 2011-04-01 2018-02-09 C.Ris Pharma Peptides isoles et purifies a partir de testicules de roussette
LT3892295T (lt) 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
TW201302800A (zh) 2011-06-10 2013-01-16 Oncotherapy Science Inc Ｓｅｍａ５ｂ胜肽及含其之疫苗
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 癌ワクチンの組み合せ物
KR20150091311A (ko) * 2012-12-04 2015-08-10 온코세라피 사이언스 가부시키가이샤 Sema5b 펩타이드 및 이를 포함하는 백신
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US20200040103A1 (en) * 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2023129460A2 (en) * 2021-12-27 2023-07-06 Memorial Sloan-Kettering Cancer Center Tumor mhc class i expression is associated with interleukin-2 response in melanoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
AU7516494A (en) * 1993-07-29 1995-02-28 Isis Pharmaceuticals, Inc. Oligomers for modulating human immunodeficiency virus
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
SE508004C2 (sv) 1996-08-07 1998-08-10 Intermec Ptc Ab Arrangemang för automatisk inställning av printrar samt material därtill
JP2002514073A (ja) * 1997-02-24 2002-05-14 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
JP2002512524A (ja) * 1997-06-03 2002-04-23 財団法人相模中央化学研究所 膜貫通ドメインを有するヒト蛋白質及びそれをコードするｄｎａ
JP2002502605A (ja) * 1998-02-09 2002-01-29 ジェンセット 分泌タンパク質をコードするｃＤＮＡ
JP2002539767A (ja) * 1998-12-22 2002-11-26 ジェンセット シグナルペプチドを含む相補的ｄｎａのコードタンパク質
WO2001000803A2 (en) * 1999-06-25 2001-01-04 Genset Apolipoprotein a-iv-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof
WO2001055317A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2001251259A1 (en) * 2000-04-07 2001-10-23 Senomyx, Inc. Novel signal transduction molecules
AU2001264721A1 (en) * 2000-05-18 2001-11-26 Incyte Genomics, Inc. G-protein coupled receptors
JP2002112793A (ja) * 2000-08-04 2002-04-16 Japan Science & Technology Corp 新規ｇ蛋白質共役受容体
WO2002012343A2 (en) * 2000-08-07 2002-02-14 Curagen Corporation Proteins and nucleic acids encoding g-protein coupled receptors
AU2001293854A1 (en) * 2000-10-04 2002-04-15 Bayer Aktiengesellschaft Regulation of human gpcr-like protein
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2460621A1 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2002364077A1 (en) * 2001-12-21 2003-07-30 Gene Logic, Inc. Gene expression profiles in stomach cancer
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030170639A1 (en) * 2002-03-11 2003-09-11 Youmin Shu Liver transmembrane protein gene
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005021793A1 (en) * 2003-08-29 2005-03-10 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

Also Published As

Publication number Publication date
EP2332980A2 (de) 2011-06-15
EP2266612A2 (de) 2010-12-29
EP2267011A3 (de) 2011-05-18
EP2267013B1 (de) 2015-11-11
EP2332980A3 (de) 2012-02-01
EP2267014A2 (de) 2010-12-29
AU2004275500B2 (en) 2011-07-14
US20080166340A1 (en) 2008-07-10
DE10344799A1 (de) 2005-04-14
EP2295077A2 (de) 2011-03-16
EP2266613A3 (de) 2011-08-03
EP2267014A3 (de) 2012-01-11
ES2634705T3 (es) 2017-09-28
EP2332983A3 (de) 2012-02-01
EP2266611A2 (de) 2010-12-29
JP2014221760A (ja) 2014-11-27
EP2266608A3 (de) 2012-01-25
CA2984653A1 (en) 2005-04-07
EP2267012A3 (de) 2011-05-04
CA2539837A1 (en) 2005-04-07
EP2267013A2 (de) 2010-12-29
JP5639989B2 (ja) 2014-12-10
EP2266612A3 (de) 2011-11-23
EP2266612B1 (de) 2018-01-03
JP5804519B2 (ja) 2015-11-04
EP2272534A3 (de) 2011-06-15
US20110135640A1 (en) 2011-06-09
EP2266616A3 (de) 2011-09-14
EP2266609A2 (de) 2010-12-29
JP5969538B2 (ja) 2016-08-17
EP2266613A2 (de) 2010-12-29
CA2814269C (en) 2017-12-19
JP5144933B2 (ja) 2013-02-13
EP2332979A3 (de) 2011-09-14
EP2266614A2 (de) 2010-12-29
EP2266614A3 (de) 2012-01-11
EP2267011A2 (de) 2010-12-29
EP2267012A2 (de) 2010-12-29
CA2814269A1 (en) 2005-04-07
JP2016199548A (ja) 2016-12-01
US9267177B2 (en) 2016-02-23
US9139880B2 (en) 2015-09-22
EP2332981A2 (de) 2011-06-15
CA2984653C (en) 2020-12-15
EP2266615A2 (de) 2010-12-29
EP2267012B1 (de) 2017-04-26
US9733251B2 (en) 2017-08-15
EP2266617A2 (de) 2010-12-29
US9910043B2 (en) 2018-03-06
EP2266608A2 (de) 2010-12-29
WO2005030250A2 (de) 2005-04-07
JP6196350B2 (ja) 2017-09-13
EP2266618A2 (de) 2010-12-29
EP2332981A3 (de) 2012-02-01
EP1664113A2 (de) 2006-06-07
EP1664113B1 (de) 2018-01-03
EP2266609A3 (de) 2012-02-01
US20160195539A1 (en) 2016-07-07
WO2005030250A3 (de) 2005-08-18
CA2539837C (en) 2017-12-19
EP2272534A2 (de) 2011-01-12
JP2007506417A (ja) 2007-03-22
EP2266615A3 (de) 2011-09-21
EP2266608B1 (de) 2016-05-25
EP2266613B1 (de) 2016-12-14
EP2295077A3 (de) 2011-08-10
EP2266618A3 (de) 2011-06-22
EP2267013A3 (de) 2011-06-08
US7875424B2 (en) 2011-01-25
EP2266611A3 (de) 2011-08-03
EP2266610A2 (de) 2010-12-29
AU2004275500A1 (en) 2005-04-07
JP2013063975A (ja) 2013-04-11
US20150376718A1 (en) 2015-12-31
EP2332983A2 (de) 2011-06-15
US20160053332A1 (en) 2016-02-25
EP2266617A3 (de) 2012-01-25
CA3096188A1 (en) 2005-04-07
JP2012110324A (ja) 2012-06-14
EP2266616A2 (de) 2010-12-29
EP2266610A3 (de) 2012-01-25
EP2332979A2 (de) 2011-06-15
US20130280166A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
US9910043B2 (en) Identification of tumor-associated cell surface antigens for diagnosis and therapy
US10036753B2 (en) Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012233057B2 (en) Identification of tumour-associated cell surface antigens for diagnosis and therapy
AU2015201738B2 (en) Identification of tumour-associated cell surface antigens for diagnosis and therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201014

EEER Examination request

Effective date: 20201014

EEER Examination request

Effective date: 20201014